Phase I Studies of the Safety and Immunogenicity of Primary and Secondary BCG Vaccination Delivered Intradermally, Orally and by Combined Routes of Administration in Healthy and Previously Immunologically Naive Volunteers.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs BCG vaccine (Primary)
- Indications Tuberculosis
- Focus Adverse reactions; Pharmacodynamics
- 12 Nov 2019 Biomarkers information updated
- 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Aug 2011 Planned end date changed from 1 Dec 2010 to 1 Jun 2012 as reported by ClinicalTrials.gov.